MTN-001 Study Schema.

Formulations: Oral, 300 mg tenofovir disoproxil fumarate; Vaginal, 1% tenofovir gel.Sampling occurs at the 3-week mid-point (blood only) and 6-week end of period visit (blood, PBMC, vaginal biopsy [intensive sites], vaginal fluid, and rectal fluid [Bronx-Lebanon site]).Number of samples at each visit varied between intensive (US) and non-intensive (African) clinical sites.